Liver cancer is the fourth most prevalent and the second most lethal cancer in China.
Hepatitis B virus (HBV) infection represents a major risk factor for hepatocellular carcinoma …

Background and Aims Regardless of great progress in early detection of hepatocellular
carcinoma (HCC), unresectable HCC (uHCC) still accounts for the majority of newly …

Background Whether intensity-modulated radiotherapy (IMRT) can enhance the efficacy of
the programmed death (PD)-1 inhibitors combined with anti-angiogenic therapy for …

Conventional clinical monotherapies for advanced hepatocellular carcinoma (HCC) have
numerous limitations. Integrated oncology approaches can improve cancer treatment …

Background Unresectable hepatocellular carcinoma (u-HCC) still accounts for the majority
of newly diagnosed HCC which with poor prognosis. In the era of systemic therapy …

Due to its widespread occurrence and high mortality rate, hepatocellular carcinoma (HCC) is
an abhorrent kind of cancer. Immunotherapy is a hot spot in the field of cancer treatment …

Purpose The current therapeutic strategies for high-risk, unresectable hepatocellular
carcinoma (HCC) patients demonstrate suboptimal outcomes. This study aimed to assess …

Background Hepatocellular carcinoma (HCC) is the sixth most common cancer globally, with
limited therapies and unsatisfactory prognosis once in the advanced stages. With promising …

Aim To evaluate the feasibility of computed tomography (CT)-derived measurements of body
composition parameters to predict the risk factor of non-objective response (non-OR) in …

Hepatocellular carcinoma (HCC) is the most common primary liver cancer worldwide. The
onset of the disease is occult and develops rapidly. As a result, the disease is often detected …